Cargando…
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
INTRODUCTION: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA). Potent antitumoral activity of scFv(FRP5)-ETA against ErbB2-overex...
Autores principales: | von Minckwitz, Gunter, Harder, Sebastian, Hövelmann, Sascha, Jäger, Elke, Al-Batran, Salah-Eddin, Loibl, Sibylle, Atmaca, Akin, Cimpoiasu, Christian, Neumann, Antje, Abera, Aklil, Knuth, Alexander, Kaufmann, Manfred, Jäger, Dirk, Maurer, Alexander B, Wels, Winfried S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242130/ https://www.ncbi.nlm.nih.gov/pubmed/16168106 http://dx.doi.org/10.1186/bcr1264 |
Ejemplares similares
-
Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
por: von Minckwitz, Gunter, et al.
Publicado: (2006) -
Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
por: Schmidt, M., et al.
Publicado: (1997) -
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007) -
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020) -
scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)